Skip To Main Content
Virginia Li on Muck Rack

Virginia Li

Verified
As seen in: FirstWord Pharma, BioCentury

Get in touch with Virginia

Contact Virginia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Virginia Li’s Journalist Portfolio

See all →
How Cornerstone's CPI-613 leapfrogged to pivotal trials in AML, pancreatic cancer

How Cornerstone's CPI-613 leapfrogged to pivotal trials in AML, pancreatic cancer

Cornerstone Pharmaceuticals Inc. was planning a traditional development pathway for CPI-613 in acute myelogen…

View article →
Why Frazier, Pivotal co-led $60M series B for vaccine play SutroVax

Why Frazier, Pivotal co-led $60M series B for vaccine play SutroVax

Frazier Healthcare Partners had been tracking SutroVax Inc.'s progress since it spun out of Sutro Biopharma I…

View article →
Solasia becomes Japan's first public biotech in months and looks to China

Solasia becomes Japan's first public biotech in months and looks to China

After becoming the first Japanese biotech to go public in 18 months, Solasia Pharma K.K. (Tokyo:4597) plans t…

View article →
Mitsubishi UFJ Capital closes ¥10 billion fund

Mitsubishi UFJ Capital closes ¥10 billion fund

Print PDF Mitsubishi UFJ Capital Co. Ltd. launched Mitsubishi UFJ Life Science I L.P. with ¥10 billion ($89 m…

View article →
Pivotal to focus on expanding team to fulfill long-term goal of building newcos

Pivotal to focus on expanding team to fulfill long-term goal of building newcos

Newly launched Pivotal bioVenture Partners plans to join syndicates funding early stage companies until it fi…

View article →
How Biomatics garnered interest in its debut $200M early stage healthcare fund

How Biomatics garnered interest in its debut $200M early stage healthcare fund

To generate interest from LPs in their inaugural healthcare fund, the duo behind Biomatics Capital Partners p…

View article →

Articles

Physician Views Preview: Taking the temperature on new and emerging SCD therapies 

|
By Virginia Li Verified
| FirstWord Pharma Verified
As Vertex Pharmaceuticals, CRISPR Therapeutics and Genetix Biopharmaceuticals continue to grapple with slow rollouts for their respective sickle cell disease (SCD) gene therapies, Agios Pharmaceuticals and Novo Nordisk are hoping to fill the treatment void with their own oral disease-modifying therapies.
Open in Who Shared Issue with article?

Physician Views Preview: Assessing prescribing trends in a changing MASH market 

|
By Virginia Li Verified
| FirstWord Pharma Verified
The metabolic dysfunction-associated steatohepatitis (MASH) landscape has undergone an enormous transformation in the last two years, starting with the 2024 approval of Madrigal's Rezdiffra (resmetirom) for MASH patients with F2 or F3 fibrosis. While the THR-β agonist managed to reach blockbuster status within a mere six quarters of its launch, Novo Nordisk's Wegovy (semaglutide) quickly threatened to challenge Rezdiffra's reign after gaining FDA approval last August in the same population.
Open in Who Shared Issue with article?

KOL Views Preview: Can Tepezza's subcutaneous formulation keep it ahead of emerging competition in thyroid eye disease? 

|
By Virginia Li Verified
| FirstWord Pharma Verified
On the back of a positive Phase III readout for Amgen’s subcutaneous (SC) Tepezza (teprotumumab-trbw), FirstWord will host an expert call in the coming weeks to discuss what role the IGF-1R inhibitor could play in treating thyroid eye disease (TED).
Open in Who Shared Issue with article?
See all 553 articles